Eupraxia Pharmaceuticals Inc. cash flow statement

In fiscal 2025, Eupraxia Pharmaceuticals Inc.'s operations generated −$28.6m of cash.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Eupraxia Pharmaceuticals Inc.: cash flow statement, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	−21	−30	−29
Depreciation and amortisation	0	0	0
Stock-based pay	1	3	9
Shares issued	16	23	74

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Eupraxia Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Eupraxia Pharmaceuticals Inc.